Close

Iovanace Biotherapeutics (IOVA) PT Lowered to $13 at Stifel, Buy Rating Maintained, "Stock Reaction Seems Overdone" May 27, 2022 06:14AM
Iovanace Biotherapeutics (IOVA) PT Lowered to $27 at Oppenheimer on Disappointing lifileucel Data, Reiterated at Buy May 27, 2022 06:06AM
Stifel Reiterates Buy Rating, $26 Price Target on Iovanace Biotherapeutics (IOVA) May 6, 2022 05:59AM
Stifel Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA), Sees Stock Trading into Mid-$20s/sh If TIL Assay is Approved/De-risked Apr 6, 2022 06:17AM
Cowen Reiterates Outperform Rating on Iovanace Biotherapeutics (IOVA) Apr 6, 2022 05:59AM


Jan 28, 2022 06:43AM Iovanace Biotherapeutics (IOVA) Upgraded to Buy at Stifel, FDA Hire Likely to Help Resolve Assay Potency Issue